Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of XW003 vs Dulaglutide in T2DM
NCT05680129Phase 3Completed
- Sponsor
- Sciwind Biosciences
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of ecnoglutide in type 2 diabetes mellitus (T2DM), sponsored by Sciwind Biosciences. Started Jan 2023; status: completed.
02
Drugs
ecnoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05680129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05680129.